Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SARS-CoV-2 spike glycoprotein (B.1.351 variant) (Spike protein (B.1.351); S protein (B.1.351); Beta spike protein)
- Target
- Spike protein (B.1.351); S protein (B.1.351); Beta spike protein
- Molecular classification
- Viral glycoprotein, Type I membrane protein, Receptor-binding protein, Fusion protein, Other (viral spike protein)
01
Overview
The SARS-CoV-2 B.1.351 spike glycoprotein is a trimeric, heavily glycosylated surface protein, consisting of S1 and S2 subunits. The S1 subunit includes the receptor-binding domain (RBD) containing key mutations (N501Y, K417N, E484K) that enhance binding affinity for the human ACE2 receptor and confer significant immune escape from neutralizing antibodies. This spike variant mediates viral entry by inducing membrane fusion upon ACE2 binding, and its structural changes increase both transmissibility and resistance to immune responses. Because of its essential role in infection and antigenicity, it is the main target for COVID-19 vaccines, diagnostics, and therapeutics, making it central to pandemic control efforts
- Other names
- Spike glycoprotein (Beta variant)S protein (B.1.351)SARS-CoV-2 Beta variant spike501Y.V2 spikeB.1.351 S proteinS-glycoprotein (B.1.351)
02
Mechanism of action
Neutralizing antibodies bind spike protein, block ACE2 interaction; Protease inhibitors block S protein cleavage, preventing membrane fusion
03
Biological functions
Receptor binding (ACE2)Membrane fusionImmune evasionViral entry
04
Disease associations
Infection (COVID-19)Immune escapeIncreased transmissibilityOther (COVID-19 pathogenesis)
05
Safety considerations
Immune escape leading to vaccine breakthroughRisk of antibody-dependent enhancement (ADE) (theoretical concern)Rapid mutation potentially reducing therapeutic efficacy
06
Interacting drugs
Monoclonal antibodies (e.g., casirivimab, imdevimab, bamlanivimab, etesevimab)
2 more in the full profile.
07
Biomarkers
Spike protein mutations (N501Y, K417N, E484K)Viral load (quantitative spike RNA/protein detection)Anti-spike antibody titers (for immune monitoring)
Beyond the preview
Go deeper on SARS-CoV-2 spike glycoprotein (B.1.351 variant) (Spike protein (B.1.351); S protein (B.1.351); Beta spike protein).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 spike glycoprotein (B.1.351 variant) (Spike protein (B.1.351); S protein (B.1.351); Beta spike protein).